Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 64 results.
User Information
Export Records
  1. 1.   GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity
  2. Heitzeneder, Sabine; Bosse, Kristopher R.; Zhu, Zhongyu; Zhelev, Doncho; Majzner, Robbie G.; Radosevich, Molly T.; Dhingra, Shaurya; Sotillo, Elena; Buongervino, Samantha; Pascual-Pasto, Guillem; Garrigan, Emily; Xu, Peng; Huang, Jing; Salzer, Benjamin; Delaidelli, Alberto; Raman, Swetha; Cui, Hong; Martinez, Benjamin; Bornheimer, Scott J.; Sahaf, Bita; Alag, Anya; Fetahu, Irfete S.; Hasselblatt, Martin; Parker, Kevin R.; Anbunathan, Hima; Hwang, Jennifer; Huang, Min; Sakamoto, Kathleen; Lacayo, Norman J.; Klysz, Dorota D.; Theruvath, Johanna; Vilches-Moure, Jose G.; Satpathy, Ansuman T.; Chang, Howard Y.; Lehner, Manfred; Taschner-Mandl, Sabine; Julien, Jean-Phillipe; Sorensen, Poul H.; Dimitrov, Dimiter S.; Maris, John M.; Mackall, Crystal L.
  3. Cancer Cell. 2022, Jan 10; 40(1): 53-+.
  1. 2.   CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice
  2. Li, Nan; Torres, Madeline B.; Spetz, Madeline R.; Wang, Ruixue; Peng, Luyi; Tian, Meijie; Dower, Christopher M.; Nguyen, Rosa; Sun, Ming; Tai, Chin-Hsien; de Val, Natalia; Cachau,Raul; Wu, Xiaolin; Hewitt, Stephen M.; Kaplan, Rosandra N.; Khan, Javed; St Croix,Brad; Thiele, Carol J.; Ho, Mitchell
  3. Cell reports. Medicine. 2021, Jun 15; 2(6):
  1. 3.   A novel patient-derived orthotopic xenograft (PDOX) mouse model of highly-aggressive liver metastasis for identification of candidate effective drug-combinations
  2. Zhang, Zhiying; Hu, Kaiwen; Miyake, Kentaro; Kiyuna, Tasuku; Oshiro, Hiromichi; Wangsiricharoen, Sintawat; Kawaguchi, Kei; Higuchi, Takashi; Razmjooei, Sahar; Miyake, Masuyo; Chawla, Sant P; Singh,Shree Ram; Hoffman, Robert M
  3. Scientific reports. 2020, Nov 18; 10(1): 20105.
  1. 4.   Mesothelin enhances tumor vascularity in newly forming pancreatic peritoneal metastases
  2. Avula, Leela Rani; Rudloff, Michael; El-Behaedi, Salma; Arons, Danielle; Albalawy, Rakan; Chen,Jack; Zhang, Xianyu; Alewine, Christine
  3. Molecular cancer research : MCR. 2020, FEB; 18(2): 229-239.
  1. 5.   PDE6D Inhibitors with a New Design Principle Selectively Block K-Ras Activity
  2. Siddiqui, Farid A; Alam, Catharina; Rosenqvist, Petja; Ora, Mikko; Sabt, Ahmed; Manoharan, Ganesh Babu; Bindu,Lakshman; Okutachi, Sunday; Catillon, Marie; Taylor,Troy; Abdelhafez, Omaima M; Lönnberg, Harri; Stephen,Andy; Papageorgiou, Anastassios C; Virta, Pasi; Abankwa, Daniel
  3. ACS omega. 2020, Jan 14; 5(1): 832-842.
  1. 6.   IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion
  2. Conlon, Kevin C.; Potter, E. Lake; Pittaluga, Stefania; Lee, Chyi-Chia Richard; Miljkovic, Milos D.; Fleisher, Thomas A.; Dubois, Sigrid; Bryant, Bonita R.; Petrus, Michael; Perera, Liyanage P.; Hsu, Jennifer; Figg, William D.; Peer, Cody J.; Shih, Joanna H.; Yovandich,Jason; Creekmore,Stephen; Roederer, Mario; Waldmann, Thomas A.
  3. CLINICAL CANCER RESEARCH. 2019, Aug 15; 25(16): 4945-4954.
  1. 7.   Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010
  2. Newman, D. J.; Cragg, G. M.
  3. Journal of Natural Products. 2012, Mar; 75(3): 311-335.
  1. 8.   Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296
  2. Langenkamp, E.; Zwiers, P. J.; Moorlag, H. E.; Leenders, W. P.; Croix, B. S.; Molema, G.
  3. Anti-Cancer Drugs. 2012, Feb; 23(2): 161-172.
  1. 9.   Gut microbiota and probiotics in colon tumorigenesis
  2. Zhu, Y. M.; Luo, T. M.; Jobin, C.; Young, H. A.
  3. Cancer Letters. 2011, Oct; 309(2): 119-127.
  1. 10.   Synthetic and Application Perspectives of Azapodophyllotoxins: Alternative Scaffolds of Podophyllotoxin
  2. Kumar, A.; Kumar, V.; Alegria, A. E.; Malhotra, S. V.
  3. Current Medicinal Chemistry. 2011, Sep; 18(25): 3853-3870.
  1. 11.   Discovery of 7-Hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a Tubulin Polymerization Inhibitor with Potent Antiproliferative and Tumor Vascular Disrupting Properties
  2. Flynn, B. L.; Gill, G. S.; Grobelny, D. W.; Chaplin, J. H.; Paul, D.; Leske, A. F.; Lavranos, T. C.; Chalmers, D. K.; Charman, S. A.; Kostewicz, E.; Shackleford, D. M.; Morizzi, J.; Hamel, E.; Jung, M. K.; Kremmidiotis, G.
  3. Journal of Medicinal Chemistry. 2011, Sep; 54(17): 6014-6027.
  1. 12.   Convergent Synthesis and Biological Evaluation of 2-Amino-4-(3 ',4 ',5 '-trimethoxyphenyl)-5-aryl Thiazoles as Microtubule Targeting Agents
  2. Romagnoli, R.; Baraldi, P. G.; Brancale, A.; Ricci, A.; Hamel, E.; Bortolozzi, R.; Basso, G.; Viola, G.
  3. Journal of Medicinal Chemistry. 2011, Jul; 54(14): 5144-5153.
  1. 13.   mTOR Kinase Inhibitor AZD8055 Enhances the Immunotherapeutic Activity of an Agonist CD40 Antibody in Cancer Treatment
  2. Jiang, Q.; Weiss, J. M.; Back, T.; Chan, T.; Ortaldo, J. R.; Guichard, S.; Wiltrout, R. H.
  3. Cancer Research. 2011, Jun; 71(12): 4074-4084.
  1. 14.   A novel high-affinity human monoclonal antibody to mesothelin
  2. Ho, M.; Feng, M. Q.; Fisher, R. J.; Rader, C.; Pastan, I.
  3. International Journal of Cancer. 2011, May; 128(9): 2020-2030.
  1. 15.   Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques
  2. Waldmann, T. A.; Lugli, E.; Roederer, M.; Perera, L. P.; Smedley, J. V.; Macallister, R. P.; Goldman, C. K.; Bryant, B. R.; Decker, J. M.; Fleisher, T. A.; Lane, H. C.; Sneller, M. C.; Kurlander, R. J.; Kleiner, D. E.; Pletcher, J. M.; Figg, W. D.; Yovandich, J. L.; Creekmore, S. P.
  3. Blood. 2011, May; 117(18): 4787-4795.
  1. 16.   Crystal Structure of Human Interferon-lambda 1 in Complex with Its High-Affinity Receptor Interferon-lambda R1
  2. Miknis, Z. J.; Magracheva, E.; Li, W.; Zdanov, A.; Kotenko, S. V.; Wlodawer, A.
  3. Journal of Molecular Biology. 2010, Dec; 404(4): 650-664.
  1. 17.   Plant Natural Products in Anticancer Drug Discovery
  2. Grothaus, P. G.; Cragg, G. M.; Newman, D. J.
  3. Current Organic Chemistry. 2010, Oct; 14(16): 1781-1791.
  1. 18.   Improved nonviral cancer suicide gene therapy using survivin promoter-driven mutant Bax
  2. Garg, H.; Salcedo, R.; Trinchieri, G.; Blumenthal, R.
  3. Cancer Gene Therapy. 2010, Mar; 17(3): 155-163.
  1. 19.   The Neurofibromatosis Type 1 Tumor Suppressor Controls Cell Growth by Regulating Signal Transducer and Activator of Transcription-3 Activity In vitro and In vivo
  2. Banerjee, S.; Byrd, J. N.; Gianino, S. M.; Harpstrite, S. E.; Rodriguez, F. J.; Tuskan, R. G.; Reilly, K. M.; Piwnica-Worms, D. R.; Gutmann, D. H.
  3. Cancer Research. 2010, Feb; 70(4): 1356-1366.
  1. 20.   Biological Assessment of Triazine Dendrimer: Toxicological Profiles, Solution Behavior, Biodistribution, Drug Release and Efficacy in a PEGylated, Paclitaxel Construct
  2. Lo, S. T.; Stern, S.; Clogston, J. D.; Zheng, J. W.; Adiseshaiah, P. P.; Dobrovolskaia, M.; Lim, J. D.; Patri, A. K.; Sun, X. K.; Simanek, E. E.
  3. Molecular Pharmaceutics. 2010, Jul-Aug; 7(4): 993-1006.
  1. 21.   Growth inhibition of hepatocellular carcinoma cells in vitro and in vivo by the 8-methoxy analog of WMC79
  2. Kosakowska-Cholody, T.; Cholody, W. M.; Hariprakasha, H. K.; Monks, A.; Kar, S.; Wang, M. F.; Michejda, C. J.; Carr, B. I.
  3. Cancer Chemotherapy and Pharmacology. 2009 63(5): 769-778.
  1. 22.   Immunologic and Therapeutic Synergy of IL-27 and IL-2: Enhancement of T Cell Sensitization, Tumor-Specific CTL Reactivity and Complete Regression of Disseminated Neuroblastoma Metastases in the Liver and Bone Marrow
  2. Salcedo, R.; Hixon, J. A.; Stauffer, J. K.; Jalah, R.; Brooks, A. D.; Khan, T.; Dai, R. M.; Scheetz, L.; Lincoln, E.; Back, T. C.; Powell, D.; Hurwitz, A. A.; Sayers, T. J.; Kastelein, R.; Pavlakis, G. N.; Felber, B. K.; Trinchieri, G.; Wigginton, J.
  3. Journal of Immunology. 2009 182(7): 4328-4338.
  1. 23.   Aprotease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity
  2. Weldon, J. E.; Xiang, L. M.; Chertov, O.; Margulies, I.; Kreitman, R. J.; FitzGerald, D. J.; Pastan, I.
  3. Blood. 2009 113(16): 3792-3800.
  1. 24.   Novel Human Interleukin-15 Agonists
  2. Zhu, X. Y.; Marcus, W. D.; Xu, W. X.; Lee, H. I.; Han, K. P.; Egan, J. O.; Yovandich, J. L.; Rhode, P. R.; Wong, H. C.
  3. Journal of Immunology. 2009 183(6): 3598-3607.
  1. 25.   Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody
  2. Cao, L.; Yu, Y. K.; Darko, I.; Currier, D.; Mayeenuddin, L. H.; Wan, X. L.; Khanna, C.; Helman, L. J.
  3. Cancer Research. 2008 68(19): 8039-8048.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel